Display options
Cite
Poursaei E, Abolghasemi M, Bornehdeli S, et al. Evaluation of hsa-let-7d-5p, hsa-let-7g-5p and hsa-miR-15b-5p plasma levels in patients with Alzheimer's disease. Psychiatr Genet. 2022;32(1):25-29doi: 10.1097/YPG.0000000000000303.
Poursaei, E., Abolghasemi, M., Bornehdeli, S., Shanehbandi, D., Asadi, M., Sadeghzadeh, M., Rahmanpour, D., & Sadeh, R. N. (2022). Evaluation of hsa-let-7d-5p, hsa-let-7g-5p and hsa-miR-15b-5p plasma levels in patients with Alzheimer's disease. Psychiatric genetics, 32(1), 25-29. https://doi.org/10.1097/YPG.0000000000000303
Poursaei, Elham, et al. "Evaluation of hsa-let-7d-5p, hsa-let-7g-5p and hsa-miR-15b-5p plasma levels in patients with Alzheimer's disease." Psychiatric genetics vol. 32,1 (2022): 25-29. doi: https://doi.org/10.1097/YPG.0000000000000303
Poursaei E, Abolghasemi M, Bornehdeli S, Shanehbandi D, Asadi M, Sadeghzadeh M, Rahmanpour D, Sadeh RN. Evaluation of hsa-let-7d-5p, hsa-let-7g-5p and hsa-miR-15b-5p plasma levels in patients with Alzheimer's disease. Psychiatr Genet. 2022 Feb 01;32(1):25-29. doi: 10.1097/YPG.0000000000000303. PMID: 34955516.
Copy Download .nbib Format: NLM
Share it on

Psychiatr Genet. 2022 Feb 01;32(1):25-29. doi: 10.1097/YPG.0000000000000303.

Evaluation of hsa-let-7d-5p, hsa-let-7g-5p and hsa-miR-15b-5p plasma levels in patients with Alzheimer's disease.

Psychiatric genetics

Elham Poursaei, Mahsa Abolghasemi, Soghra Bornehdeli, Dariush Shanehbandi, Milad Asadi, Mahsa Sadeghzadeh, Dara Rahmanpour, Reza Naghdi Sadeh

Affiliations

  1. Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Tabriz, Iran.
  2. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  3. Department of Basic Oncology, Ege University, Institute of Health Sciences, Izmir, Turkey.
  4. Student research committee, Tabriz University of Medical Sciences, Tabriz, Iran.
  5. Research Center of Psychiatry and Behavioral Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.

PMID: 34955516 DOI: 10.1097/YPG.0000000000000303

Abstract

BACKGROUND: Alzheimer's disease (AD) is a progressive neurodegenerative disorder MicroRNAs (miRNAs) may be promising diagnostic biomarkers for AD. Previous evidence shows that miR-15b-5p, hsa-let7g-5p and hsa-let7d-5p might confer potential blood biomarkers for timely diagnosis of AD. Therefore, in this replication study, we aimed to investigate the serum transcript level of these miRNAs to assess for their potential as diagnostic or prognostic biomarker in AD patients.

METHODS: Blood samples were obtained from 50 AD patients and 50 age- and sex-matched healthy individuals. Then, total RNA was extracted from serum samples, cDNA was synthesized, and the expression level of miRNAs was measured by the real-time PCR method.

RESULTS: The expression level of hsa-let7d-5p (fold change = 2.14, P = 0.007) and hsa-let7g-5p (fold change = 1.94; P = 0.013) was significantly increased in the AD patients compared to control individuals. However, the difference in the transcription of miR-15b-5p between the two groups was not statistically significant (fold change = 1.08; P = 0.76). The AROC for transcript levels of hsa-let-7d-5p was 0.68 (P = 0.014; 95% CI, 0.39-0.88) and it was 0.64 for hsa-let-7g-5p (P = 0.028; 95% CI, 0.27-0.89). The cut-off value for let-7d-5p had 0.82 sensitivity and 0.34 specificity. Moreover, the cut-off value for hsa-let-7g-5p indicated a 0.79 sensitivity and 0.28 specificity.

CONCLUSION: Our findings suggest the potential of measuring the transcript levels of hsa-let7d-5p and hsa-let7g-5p miRNAs as a diagnostic biomarker for AD.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

References

  1. Butterfield DA, Halliwell B Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci. (2019). 20;148–160 - PubMed
  2. De Felice FG, Ferreira ST Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer’s disease. Cell Mol Neurobiol. (2002). 22;545–563 - PubMed
  3. De Felice FG, Houzel JC, Garcia-Abreu J, Louzada PR Jr, Afonso RC, Meirelles MN, et al. Inhibition of Alzheimer’s disease beta-amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: implications for Alzheimer’s therapy. FASEB J. (2001). 15;1297–1299 - PubMed
  4. DeTure MA, Dickson DW The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. (2019). 14;32 - PubMed
  5. Engedal K, Snaedal J, Hoegh P, Jelic V, Bo Andersen B, Naik M, et al. Quantitative EEG applying the statistical recognition pattern method: a useful tool in dementia diagnostic workup. Dement Geriatr Cogn Disord. (2015). 40;1–12 - PubMed
  6. Feng L, Liao YT, He JC, Xie CL, Chen SY, Fan HH, et al. Plasma long non-coding RNA BACE1 as a novel biomarker for diagnosis of Alzheimer disease. BMC Neurol. (2018). 18;4 - PubMed
  7. Frost B, Jacks RL, Diamond MI Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. (2009). 284;12845–12852 - PubMed
  8. Gao J, Garulacan LA, Storm SM, Opiteck GJ, Dubaquie Y, Hefta SA, et al. Biomarker discovery in biological fluids. Methods. (2005). 35;291–302 - PubMed
  9. Gorabi AM, Aslani S, Barreto GE, Báez-Jurado E, Kiaie N, Jamialahmadi T, et al. The potential of mitochondrial modulation by neuroglobin in treatment of neurological disorders.Free Radic Biol Med. (2021) 162;471–7 - PubMed
  10. Ha M, Kim VN Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. (2014). 15;509–524 - PubMed
  11. Hu YB, Li CB, Song N, Zou Y, Chen SD, Ren RJ, Wang G Diagnostic value of microRNA for Alzheimer’s disease: a systematic review and meta-analysis. Front Aging Neurosci. (2016). 8;13 - PubMed
  12. Kocahan S, Doğan Z Mechanisms of Alzheimer’s disease pathogenesis and prevention: the brain, neural pathology, N-methyl-D-aspartate receptors, tau protein and other risk factors. Clin Psychopharmacol Neurosci. (2017). 15;1–8 - PubMed
  13. Kumar P, Dezso Z, MacKenzie C, Oestreicher J, Agoulnik S, Byrne M, et al. Circulating miRNA biomarkers for Alzheimer’s disease. PLoS One. (2013). 8;e69807 - PubMed
  14. Kumar S, Reddy PH Are circulating microRNAs peripheral biomarkers for Alzheimer’s disease? Biochim Biophys Acta. (2016). 1862;1617–1627 - PubMed
  15. Lambert JC, Amouyel P Genetics of Alzheimer’s disease: new evidences for an old hypothesis? Curr Opin Genet Dev. (2011). 21;295–301 - PubMed
  16. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. (2011). 7;263–269 - PubMed
  17. Mendes-Silva AP, Pereira KS, Tolentino-Araujo GT, Nicolau EdeS, Silva-Ferreira CM, Teixeira AL, Diniz BS Shared biologic pathways between Alzheimer disease and major depression: a systematic review of microRNA expression studies. Am J Geriatr Psychiatry. (2016). 24;903–912 - PubMed
  18. Nagaraj S, Zoltowska KM, Laskowska-Kaszub K, Wojda U microRNA diagnostic panel for Alzheimer’s disease and epigenetic trade-off between neurodegeneration and cancer. Ageing Res Rev. (2019). 49;125–143 - PubMed
  19. Pandya R, Nadiadwala S, Shah R, Shah MJAHR Buildout of methodology for meticulous diagnosis of K-complex in EEG for aiding the detection of Alzheimer’s by artificial intelligence. Augmented Human Research. (2020). 5;1–8 - PubMed
  20. Schmittgen TD, Livak KJ Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. (2008). 3;1101–1108 - PubMed
  21. Selkoe DJ The molecular pathology of Alzheimer’s disease. Neuron. (1991). 6;487–498 - PubMed
  22. Srivastava S, Ahmad R, Khare SK Alzheimer’s disease and its treatment by different approaches: a review. Eur J Med Chem. (2021). 216;113320 - PubMed
  23. Tanzi RE The genetics of Alzheimer disease. Cold Spring Harb Perspect Med. (2012). 2;a006296 - PubMed

Publication Types